Late breaking paper from scientist at Merck & Co., showing the characterization of Keytruda microcrystalline suspension using magic angle spinning (MAS) NMR. mAb microcrystals have the potential to deliver biotherapeutics to patients at a high concentration and in a small volume though subcutaneous injection, as opposed to more diluted formulation, delivered intravenous, which requires patient's visits to hospitals.
